Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (191-200 of 264) with videos related to

Pageof 27
Sort By:
Nature Communications|March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Matteo Dugo, Marco Barreca, et al.
Journal of the National Cancer Institute|January 31, 2008
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale, Meredith M Regan, Mauro G Mastropasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II TrialSilvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized StudyMassimo Cristofanilli, Hope S Rugo, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II TrialAntonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2024
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancerMonica Milano, Carmine Valenza, Annamaria Ferrari, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 23, 2020
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-upSabrina Kahler-Ribeiro-Fontana, Eleonora Pagan, Francesca Magnoni, et al.
Pageof 27

Showing results (191-200 of 264) with videos related to

Sort By:
Pageof 27
Nature Communications|March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Matteo Dugo, Marco Barreca, et al.
Journal of the National Cancer Institute|January 31, 2008
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale, Meredith M Regan, Mauro G Mastropasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II TrialSilvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized StudyMassimo Cristofanilli, Hope S Rugo, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II TrialAntonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2024
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancerMonica Milano, Carmine Valenza, Annamaria Ferrari, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 23, 2020
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-upSabrina Kahler-Ribeiro-Fontana, Eleonora Pagan, Francesca Magnoni, et al.
Pageof 27